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The present study aimed to evaluate the effect of the adjuvant use of resveratrol with meloxicam on the 
clinical scores of knee OA patients. This was a double-blind placebo-controlled randomised trial involving 
100 patients with knee osteoarthritis performed at the Shar Teaching Hospital, Sulaimani General Hospital 
and Specialised Rheumatology Center, Sulaimani City from December 2016 to September 2017. The 
efficacy of the treatment was evaluated by measuring the changes from baseline in the KOOS score, 
WOMAC index, and VAS-100 score after 90 days of treatment. Resveratrol significantly improves the 
knee OA pain and associated symptoms compared with placebo, and both clinical scores were found to 
be eligible for following treatment outcomes. In conclusion, resveratrol, when used in combination with 
meloxicam, improves pain and symptom scores in patients with mild-to-moderate knee OA compared 
with placebo. The intervention with a dietary supplement may significantly impact the pain and overall 
quality of life in patients with knee OA.
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INTRODUCTION
Knee osteoarthritis (OA) is a slowly progressive 
chronic degenerative and disabling disease of the 
articulating knee joints, which mostly arises after hyaline 
cartilage damage (Loeser et al., 2012). Although it is 
considered the most common musculoskeletal disorder 
mainly affecting people over 65 years old (Mobasheri, 
Batt, 2016), it also affects active younger patients, 
as a result of physical trauma or due to the long-term 
participation in highly demanding sports (Buckwalter, 
Martin, 2004). As a result of continuous progressive 
inflammatory changes that predispose to many painful 
symptoms, knee OA affects many aspects of the patient’s 
life, including the ability to perform normal daily 
functions, sitting, walking and climbing stairs (Kraus 
et al., 2015), which may result in a poor quality of life 
(Johnson, Hunter, 2014). Moreover, knee OA is highly 
associated with morbidity in the community (Hayami, 
2008). In spite of advances in the elaboration of cellular 
and molecular mechanisms of OA pathogenesis and the 
identification of more sensitive and reliable biomarkers 
as diagnostic tools (Mobasheri et al., 2017), there is no 
optimal therapy that slows cartilage breakdown or reverses 
the progression of cartilage degradation and other tissue 
damage. In addition to non-pharmacological approaches 
to treatment, many drugs are used in the pharmacological 
treatment of OA; non-steroidal anti-inflammatory agents 
(NSAIDs) are the most widely used for their analgesic 
and anti-inflammatory activities, which effectively reduce 
the symptoms of OA (Nelson et al., 2014). However, the 
long-term use of these drugs was correlated with many 
important adverse events, including an increased risk of 
gastrointestinal bleeding, cardiovascular disorders and 
an increased bleeding tendency due to platelet activation 
(Zhang et al., 2007; Varas-Lorenzo et al., 2013). Currently, 
there is a growing interest in developing therapeutic 
strategies to decrease the progressive degeneration of joint 
tissues with fewer side effects. In this regard, numerous 
studies have recently focused on the potential effects of 
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natural compounds, including nutraceuticals, to halt the 
progression of OA and reduce any associated symptoms 
(Hussain et al., 2009; Moura et al., 2016). Resveratrol is a 
natural polyphenol extracted from Polygonum cuspidatum, 
which shows pleiotropic properties that suggest it may be 
applied for many therapeutic uses, including the treatment 
of cancer, cardiovascular diseases, and metabolic disorders 
(Neves, Nunes, Reis, 2016). Meanwhile, many preclinical 
studies have revealed the anti-inflammatory properties of 
resveratrol that might enable the degenerative articular 
damage to be ameliorated in vitro and in experimental 
animals (Jiang et al., 2017; Ma et al., 2015). Additionally, 
resveratrol inhibits the destruction of the cartilage matrix 
by protecting matrix proteins, proteoglycans, collagen 
type II and aggrecans, against the effects of the matrix 
metalloproteinases (MMPs) or inflammatory stimuli (i.e., 
iNOS, COX2) (Nguyen et al., 2017). Pre-clinical findings 
support the safety of resveratrol, and toxicity studies 
on different animal species did not reveal any serious 
adverse effects (Williams et al., 2009; Johnson et al., 
2011). Based on previous data, resveratrol did not produce 
any apparent adverse effects up to a dose of 1.0 g in the 
short-term. However, when patients administered 2.5g/
day or more, diarrhoea, vomiting, nausea and evidence 
of liver dysfunction were reported in patients with non-
alcoholic fatty liver disease (Brown et al., 2010; La Porte 
et al., 2010). Interestingly, no serious side effects were 
reported in long-term clinical trials using low doses of 
resveratrol (Tomé-Carneiro et al., 2013), and resveratrol 
was found to be safe and reasonably well-tolerated up to 
5.0 g/day, either as a single dose or as part of a multiple-
day dosing regimen (Patel et al., 2011). In spite of the 
presence of a tremendous amount of in vitro and in vivo 
data on the chondroprotective and regenerative capacity 
of resveratrol, no clinical trials exist to date that have 
determined the effectiveness of resveratrol in the treatment 
of knee OA. The present study was designed to evaluate 
the effect of adjuvant use of resveratrol with meloxicam 
on the clinical scores of knee OA patients.
MATERIAL AND METHODS 
Study design 
A prospective double-blind placebo-controlled 
randomised multi-centre trial was performed to evaluate 
the efficacy of adjuvant use of resveratrol (Res) with 
meloxicam (Mlx) against placebo (starch powder) on 
improving the symptoms of knee OA. The present study 
was conducted over a period of 10 months; the first patient 
was included in December 2016 and the last patient 
completed follow-up in September 2017. The research was 
conducted at Shar Teaching Hospital, Sulaimani General 
Hospital and the Specialised Rheumatology Center, 
Sulaimani City. The research protocol was approved 
by the Research Ethics Committee of the College of 
Medicine, University of Sulaimani (No. 42 in 21/11/2016) 
in accordance with the Declaration of Helsinki and its 
amendments, as well as the Guidelines for Good Clinical 
Practices issued by the Committee of Propriety Medicinal 
Products of the European Union. All participants were 
asked to sign a written informed consent voluntarily 
before participation in the study. Patient safety was closely 
monitored by a board of specialists by conducting regular 
meetings during the study. 
Patient inclusion and randomisation
One hundred and fourteen patients were screened 
for eligibility. Based on the criteria for OA diagnosis 
(American College of Rheumatology; ACR), and the 
methods found in previously published studies, a hundred 
eligible patients of both sexes (age range 45-75 years) with 
clinical evidence of knee OA were diagnosed by a senior 
rheumatologist and orthopaedic clinician according to the 
American College of Rheumatology criteria (Altman et 
al., 1986); the results of radiographic diagnosis were of 
mild-to-moderate knee OA (grade I–III) according to the 
Kellgren–Lawrence classification (Kellgren, Lawrence, 
1957), defined by the presence of typical knee symptoms 
(pain, stiffness, disability) and radiographic markers 
of OA. Other inclusion criteria were knee complaints 
surpassing the threshold indicated by at least two of the 
following questionnaires: maximal 60 points out of 96 
points on the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC), maximal 40 points on the 
Knee injury and Osteoarthritis Outcome Score (KOOS), 
and minimal 40 mm for the 100-mm Visual Analogue 
Scale (VAS) for pain. Patients were excluded if they had 
an established diagnosis of a bleeding disorder; currently 
used antioxidant-containing drugs or dietary supplements 
that contain polyphenols, anticoagulants, or antiplatelet 
therapy; or presence of an allergy to any of the ingredients 
used in the present study. The use of NSAIDs, other than 
that indicated during the trial period (meloxicam), was not 
allowed. The participants were advised not to use any other 
analgesics or anti-inflammatory agents. The participants 
were randomised (3:2 ratio) by independent outpatient 
units. A simple randomisation technique was followed, 
in which the predetermined sample size for treatment 
group (n=60) and placebo (n=40) were shuffled in opaque 
envelopes containing an identifier for treatment group 
Clinical efficacy of resveratrol as an adjuvant with meloxican in the treatment of knee osteoarthritis patients
Braz. J. Pharm. Sci. 2018;54(4):e17773 Page 3 / 10
and an identifier for placebo. The order of the shuffled 
envelopes determined the allocation of participants 
to one of the treatments. The process was relatively 
simple to organise, preserves the predetermined design 
parameters, and can be readily extended to situations of 
long recruitment duration. The control group initiated 
treatment with 15 mg meloxicam (Standardised 98% 
pure; Boehringer Ingelheim, Germany) and placebo 
formula specially prepared for the study (Mlx+placebo) 
orally once per day for 90 days; the resveratrol group 
received 15 mg meloxicam with 500 mg resveratrol 
(Sigma-Aldrich, UK) orally once per day for 90 days 
(Mlx+Res). Based on the literature review, most of the 
investigations on bioactive polyphenols need no less than 
90 days for the treatment period to achieve a satisfactory 
response such as analgesic and/or anti-inflammatory 
effects. The placebo was formulated as hard gelatine 
capsules with an identical colour, form and size as the 
resveratrol capsules. All of those involved in the trial 
(investigators, participants, staff collecting data, and 
statistician) were blinded to the randomisation. The 
patients using anti-inflammatory drugs before inclusion 
were held in a 2 week washout period. During this period, 
oral or local administration was gradually withdrawn 
within a week after enrolment and then the patients did 
not receive any drug for the following week; after this, 
each patient was assigned to one of the treatment groups 
of the trial. Recruited patients were asked to carry on 
with their regular daily activities that they had been 
undertaking before inclusion and were also advised 
to continue the same until the end of the trial period. 
Additionally, patients were asked to return the empty 
containers of trial drugs at every follow-up visit in order 
to check their compliance with the protocol of drug use. 
The patients were free to stop participating in the study 
at any time without prior permission of the investigator 
or any reason. Furthermore, the investigator was able 
to remove any patient from the study who developed 
adverse effects or showed non-compliance with the 
treatment protocol.
Follow-up assessment
The included patients attended the assigned out-
patient clinic for follow-up visits on day 0 (First visit), day 
30 (Second visit), day 60 (Third visit), and day 90 (Last 
visit). During each follow-up visit, general and systemic 
physical examinations were performed. The evaluation 
of knee OA symptoms was performed utilising the total 
KOOS score (Salavati et al., 2011), total WOMAC index 
(Bellamy et al., 1988) and visual analogue score for pain 
(VAS-100) (Haq, Davatchi, 2011) to assess pain as a 
primary outcome. Global assessment of disease severity 
score was assessed by both the investigators and subjects 
on every follow-up visit to determine the efficacy of 
the treatment. As a primary outcome, the efficacy of 
the treatment was evaluated by measuring the change 
from baseline in the KOOS score, WOMAC index, and 
the VAS-100 score; these were measured at baseline, 
and at 30, 60 and 90 days of the out-patient visits. The 
secondary outcomes were measurement of the changes 
in KOOS subscale scores (symptom, pain, daily activity, 
sport and quality of life) of knee OA severity, changes 
in WOMAC subscale scores (stiffness, pain and daily 
functions), adverse drug reactions, and compliance with 
treatment protocols. Adherence to the medication protocol 
was monitored through behavioural and telephone-based 
interventions on regular monthly follow-up bases.
Statistical analysis
The analysis of data was performed using GraphPad 
Prism 5.0.1 program (GraphPad Software Inc., CA, USA). 
The baseline demographic data and patient characteristics 
were compared between the treatment groups using the 
Chi-square test for categorical and unpaired t-test to 
compare between the means of different groups at baseline. 
Continuous variables were analysed using the paired t-test 
and the two-way ANOVA confirmed by Bonferroni’s 
post hoc test. Spearman’s correlation and ROC analysis 
were utilised to compare the outcomes of questionnaires. 
A p value <0.05 was considered to indicate statistical 
significance.
RESULTS
A total of 114 patients were screened for eligibility; 
of these, 100 met the inclusion criteria, and were 
randomised and assigned to the trial. Only 82 patients 
completed the follow-up: 10 from the Mlx+Res group, 
and 8 from the Mlx+placebo group did not complete the 
follow-up visits for various reasons (Figure 1).
Baseline characteristics
The baseline comparative demographic data 
between the patients with knee OA in the Mlx+placebo 
and Mlx+Res groups are shown in Table I. There were 
no significant differences in age, sex, body weight, body 
mass index, and disease grade or disease duration between 
the two groups. Sex was not a potential variable in the 
present study based on the absence of any differences in 
B. H. Marouf, S. A. Hussain, Z. S. Ali, R. S. Ahmmad
Braz. J. Pharm. Sci. 2018;54(4):e17773Page 4 / 10
FIGURE 1 - Flow chart of patient inclusion and follow-up. n: number of patients; OA: osteoarthritis; RA: rheumatoid arthritis; 
WOMAC: Western Ontario and McMaster Universities Arthritis Index; VAS: Visual Analogue Score; KOOS: Knee injury and 
Osteoarthritis Outcome Score.
TABLE I - Demographic data and baseline characteristics of the Knee OA patients treated with Meloxicam+Resveratrol (Mlx+Res) 
or Meloxicam+placebo (Mlx+placebo)
Parameters Res+Mlx, n=50 Mlx+placebo, n=32 P value
Gender n (%)
Male 13 (26) 6 (9.4) 0.03
Female 37 (74) 14 (90.6) 0.06
Age (year) 58.2±9.1 57.6±8.2 0.77
Body weight (kg) 80.5±16.1 82.4±11.0 0.55
BMI (kg/m2) 30.7±5.6 32.1±4.6 0.1
Disease duration (year) 3.5±3.2 3.9±2.9 0.45
Disease grade n (%)
Grade I 7 (14) 3 (9.4) 0.12
Grade II 25 (50) 15 (47)
Grade III 18 (36) 14 (43.6)
Baseline KOOS 33.6±9.2 33.5±10.5 0.9
Baseline WOMAC 59.6±13.7 59.3±7.4 0.2
Baseline VAS-100 (mm) 81.0±11.6 85.3±9.2 0.08
Associated diseases n (%)
Hypertension 20 (40.0) 18 (56.0) 0.10
Diabetes mellitus 8 (16.0) 3(9.4) 0.12
Smoking habits 3 (6.0) 1 (3.1) 0.11
Values are presented as percent or mean±S.D; n: number of patients; Res: Resveratrol; Mlx: Meloxicam. Chi-square and unpaired 
t-test were utilised to predict significance at P<0.05.
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treatment response between males and females. Moreover, 
the baseline total KOOS, total WOMAC and VAS-100 
scores were also not significantly different between the 
two groups.
The clinical outcome
Table II shows that adjuvant use of resveratrol 
with meloxicam significantly improves total KOOS 
score after 30 days compared with both baseline values 
and that of the Mlx+placebo group within the same 
period (P<0.05). Although the effect of resveratrol 
continues to improve KOOS score after 60 and 90 days, 
these values are not significantly different (P>0.05). 
The post-intervention KOOS score in the Mlx+placebo 
group was not significantly different for all of the time 
ranges. Moreover, the post-intervention WOMAC score 
in Mlx+Res was significantly improved at all of the time 
ranges compared with both baseline values and those 
of the Mlx+placebo group (P<0.05). Meanwhile, the 
post-intervention WOMAC score was not significantly 
changed after 90 days in this group. Additionally, Table 
II indicates that the post-intervention VAS-100 score 
was significantly improved in both groups compared to 
baseline; however, the degree of changes in Mlx+Res 
group was significantly higher compared to those 
reported in Mlx+placebo group. In Table III, the post 
intervention KOOS subscale score in Mlx+Res group was 
significantly improved in all KOOS areas compared with 
both baseline values and that reported in the Mlx+placebo 
group, which show non-significant changes in subscale 
score for the entire treatment period. Similarly, Table IV 
indicates that the post-intervention WOMAC subscale 
score in Mlx+Res group was significantly improved 
in all WOMAC subscale areas compared with baseline 
values and the corresponding results of Mlx+placebo 
group, where all of the subscale values were not 
significantly different during the treatment period. The 
validity of KOOS at different levels in the evaluation 
of treatment outcome in both groups compared with 
WOMAC was evaluated using Spearman’s correlation, 
where a significant negative correlation was detected 
in the Mlx+placebo group at most of the values greater 
than 1 (r= - 0.6, P= 0.001) (Figure  2). The influence of 
TABLE II - Effect of resveratrol (Res) as an adjuvant with meloxicam (Mlx) on the Knee Injury and Osteoarthritis Outcome Score 
(KOOS), Western Ontario and McMaster Universities Arthritis (WOMAC) index, and Visual Analogue Score (VAS-100) in patients 
with mild-to-moderate knee OA
Score
Mlx+Res, n=50 Mlx+placebo, n=32
Baseline 30 days 60 days 90 days Baseline 30 days 60 days 90 days
KOOS 33.6±9.2a 81.7±12.9*b 87.8±10.2*b 89.3±9.5*b 33.5±10.5a 38.9±15.1a 37.2±14.3a 38.3±14.8a
WOMAC 59.6±13.7a 37.2±10.5*b 24.4±8.4*c 18.0± 5.5*c 59.3±7.4a 54.2±11.1a 52.8±12.1a 50.1±14.9a
VAS-100 81.0±11.6a 29.4±11.5*b 22.3±12.5*b 18.6±10.8*b 85.3±9.2a 72.7±17.4*b 70.9±14.9*b 65.7±16.8*b
Values are presented as mean±S.D; n: number of patients; * significantly different compared with baseline values within the same 
group (paired t-test); values with different superscripts (a,b,c) are significantly different among different times and different groups 
(unpaired t-test and ANOVA; P<0.05).
TABLE III - Effect of resveratrol (Res) as adjuvant with meloxicam (Mlx) on the different areas of Knee injury 
and Osteoarthritis Outcome Score (KOOS) in patients with mild-to-moderate knee OA
KOOS area
Mlx+Res, n=50 Mlx+placebo, n=32
Baseline 30 days 60 days 90 days Baseline 30 days 60 days 90 days
Symptom 49.0±20.2a 84.8±12.6*b 89.7±11.8*b 92.1±9.6*b 38.3±17.0a 44.1±19.6a 43.8±19.9a 41.6±22.0a
Pain 32.9±14.1a 80.2±15.1*b 87.9±13.0*c 90.3±12.9*c 30.3±12.9a 39.1±18.8a 34.7±17.6a 35.5±19.0a
Daily living 38.4±14.8a 83.7±16.4*b 90.3±10.3*b 91.6±7.8*b 35.1±12.2a 39.6±16.2a 39.7±15.5a 40.9±16.1a
Sport 20.8±15.7a 63.0±17.5*b 75.2±14.9*c 74.6±15.5*c 24.5±8.8a 30.2±13.4a 23.8±14.0a 28.6±9.8a
QoL 35.3±10.6a 77.1±18.5*b 85.6±11.1*c 88.3±13.9*c 29.9±11.2a 36.7±14.2a 36.3±14.3a 39.1±10.9a
Values are presented as mean±S.D; n: number of patients; Res: Resveratrol; Mlx: Meloxicam; QoL: Quality of life; * significantly 
different compared with baseline values within the same group (paired t-test); values with different superscripts (a,b,c) are 
significantly different among different times and different groups (unpaired t-test and ANOVA; P<0.05).
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both treatment approaches on the pain score was quite 
evident; Figure 3 shows the correlation between KOOS 
score and VAS-100 score, where a high negative and 
significant correlation was observed in both groups. 
Moreover, evaluation of the sensitivity and specificity 
of the two methods using the ROC curve demonstrated 
a highly significant (P<0.0001) overlap for AUC in both 
treatment groups (AUC=1.0, Figure 4).
TABLE IV - Effect of resveratrol (Res) as an adjuvant with meloxicam (Mlx) on the different areas of Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) in patients with mild-to-moderate knee OA.
WOMAC 
area
Mlx+Res, n=50 Mlx+placebo, n=32
Baseline 30 days 60 days 90 days Baseline 30 days 60 days 90 days
Stiffness 4.3±2.2a 1.1±1.3*b 0.8±1.3*b 0.7±1.2*b 5.8±1.4a 5.3±1.8*b 5.5±1.9*b 4.6±2.3b
Pain 13.4±3.3a 3.6±3.1*b 2.1±2.6*b 1.8±2.5*b 13.8±2.4a 12.1±4.0a 12.2±4.0a 11.9±4.4a
Function 41.8±9.3a 11.3±11.1*b 7.2±7.4*b 5.9±5.4*b 44.1±8.3a 41.1±16.2a 39.6±11.6a 37.1±12.1a
Values are presented as mean±S.D; n: number of patients; Res: Resveratrol; Mlx: Meloxicam; * significantly different compared 
with baseline values within the same group (paired t-test); values with different superscripts (a,b) are significantly different among 
different times and different groups (unpaired t-test and ANOVA; P<0.05).
FIGURE 3 - Spearman’s correlation between KOOS and VAS-
100 scores in both treatment groups after 90 days. r: Spearman’s 
correlation coefficient; A: Mlx+Res group; B: Mlx+placebo 
group.
FIGURE 2 - Spearman’s correlation between KOOS and 
WOMAC scores in both treatment groups after 90 days. r: 
Spearman’s correlation coefficient; A: Mlx+Res group; B: 
Mlx+placebo group.
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DISCUSION
Despite advances in understanding the mechanisms 
and treatment of OA-associated pain, many OA patients 
experienced various levels of acute and chronic pain, which 
impairs their daily living activities and quality of life (Wang 
et al., 2016). Moreover, untreated OA pain may lead to 
serious negative impacts, like those reported in the baseline 
clinical scores of the included patients (Table I). The present 
study is the first randomised controlled clinical trial to 
provide clinical evidence regarding the efficacy of 
resveratrol in improving the symptoms and pain associated 
with knee OA, which can provide the basis for the clinical 
implementation of oral resveratrol in knee osteoarthritis pain. 
Since the symptoms of osteoarthritis were assessed mainly 
by pain, the outcomes of the present study were quantitatively 
evaluated by the severity of pain. Commonly, most studies 
in this regard used VAS of pain or pain index in WOMAC, 
while others utilised different techniques, including 
frequencies of painkiller use during the study or qualitatively 
identifying pain descriptors (Nakagawa et al., 2014; 
Cedraschi et al., 2013). Although Knee OA is a chronic 
musculoskeletal disorder that is not life-threatening, it may 
seriously influence the emotional, daily physical and social 
activity of patients. Accordingly, it negatively impacts the 
health-related quality of life. Meanwhile, effective 
pharmacological treatment not only improves pain and 
mobility but also the quality of life as a whole. Due to high 
prevalence of OA, its association with high costs of 
healthcare induced by the consumption of drugs and loss of 
work force and productivity is highly recognised (Gupta et 
al., 2005). Therefore, increasing interest in pharmacological 
agents that modulate OA progression and limit the need for 
surgical interventions were strongly encouraged. To the best 
of our knowledge, the present study is the first clinical trial 
on the effects of resveratrol, as a herbal supplement, on the 
pain and associated dysfunction scores in patients with 
evidence of knee OA. Using the KOOS, WOMAC and VAS 
questionnaire instruments approach, resveratrol 
supplementation results in significant decreases of total knee 
pain scores, and an improved disability index and overall 
health scores compared with placebo. These results support 
a role for naturally-derived supplements like resveratrol as 
an alternative or complementary treatment option in pain 
management that may also reduce surrogate markers of 
disease progression in knee OA. While our results show that 
resveratrol is superior to placebo, we noticed clinically 
important alterations in self-rated outcomes in both 
treatment groups. These were most evident with pain score; 
however, we also observed such changes in the KOOS and 
WOMAC symptom score. In the present study, 90 days of 
resveratrol use resulted in a significant improvement in the 
clinical scores of OA pain and disability in participants with 
knee OA. These clinical observations are in line with the 
available data showing that resveratrol reduces pain, 
inflammation, and oedema, as well as articular destruction 
in experimental models of arthritis (Wang, Chen, Wang, 
2016; Wang et al., 2017). Together with the previously 
reported data, the present finding supports the analgesic 
activity of dietary polyphenols in patients with mild-to-
moderate knee pain, and suggests that it is in tune with the 
results of many pilot studies reported regarding the adjuvant 
use of polyphenols and other supplements during the 
treatment of inflammatory musculoskeletal disorders like 
knee OA and rheumatoid arthritis (Hussain et al., 2009; 
Hussain et al., 2016). Although the exact mechanism behind 
the impact of resveratrol on improving OA symptoms in a 
clinical setting has not been well described, a series of 
animal experiments conducted in the past few years has 
demonstrated that the oral administration of resveratrol is 
capable of significantly preventing the progression of 
osteoarthritis (Gu et al., 2016), and also exhibits a potent 
analgesic effect in different animal models (Wang et al., 
2017; Bazzo et al., 2013). Despite the large output of 
preclinical studies dealing with the analgesic and anti-
inflammatory activities of resveratrol, there is a relative lack 
of clinical trials investigating the analgesic effect of 
resveratrol (Nguyen et al., 2017; Vang et al., 2011). Many 
updated regimens for managing OA focus on relieving pain 
and stiffness and improving physical function as important 
goals of therapy (Suokas et al., 2014; Moyer et al., 2014). 
However, the aetiology and progression of OA have been 
understood to have an inflammatory basis during the early 
FIGURE 4 - ROC curve illustrating the sensitivity and specificity 
for different values of KOOS corresponding to a WOMAC. 
ROC: Receiver operating characteristic curve.
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stages of disease (Felson, 2006), which might be associated 
with tissue damage, especially the destruction of cartilage. 
In OA, many important mediators of the altered metabolism 
and increased catabolism of joint tissues are formed based 
on the cartilage damage and increased circulating 
inflammatory factors, including pro-inflammatory cytokines 
(Kapoor et al., 2011). Moreover, inflammation and pain are 
firmly related to human health, and there is always strong 
interplay between pain and inflammation. Thus, 
inflammation is regarded as an important part of the 
pathogenesis of OA and is strongly correlated with the 
deterioration of subscales targeted through KOOS and 
WOMAC. In tune with previous reports, our findings 
support the analgesic effects of dietary polyphenols in adults 
with mild-to-moderate knee pain. The assessment of OA 
pain has been largely determined by questionnaires such as 
those based on quality of life indicators. Meanwhile, 
radiographic imaging and physical examination have been 
used to stage the disease. We used KOOS, WOMAC and 
VAS questionnaires, which have been widely employed to 
assess knee pain, quality of life, and disability in patients 
with knee OA (Mahler et al., 2016). Based on the present 
findings, resveratrol consistently improved pain scores, as 
observed across all sub-scales of KOOS and WOMAC, 
evaluating constant, intermittent, and total pain; they also 
lowered the associated scores, reflecting functional 
improvement. We observed a difference in pain scores 
assessed by VAS in our participants, which could be 
explained by the visual expression of general pain intensity 
used in VAS scoring compared to the knee OA-specific 
magnitude of knee pain numerically rated by the KOOS and 
WOMAC questionnaires. Another notable finding of the 
present study is the high level of agreement between clinical 
outcomes when assessed by either KOOS or WOMAC in 
Iraqi patients with knee OA (Figure 4), which was in line 
with previously reported data indicating that KOOS is an 
instrument with improved validity that may be at least as 
responsive as WOMAC (Roos, Toksvig-Larsen, 2003). 
Based on the limitations and strengths of each assessment 
tool for pain, it is practically recommended to utilise more 
than one instrument to capture the multi-dimensional 
aspects of OA pain. The present study has limitations that 
affect the interpretation of findings. These include the small 
sample size, and the absence of a dose-response design to 
assess effects at low vs. high doses of resveratrol. The 
included patients had mild-to-moderate radiographic knee 
OA at baseline (Kellgren–Lawrence scores of 1-3) and 
mild-to-moderate knee pain. Whether patients with more 
severe knee OA (Kellgren–Lawrence score of 4) and higher 
levels of pain would benefit from resveratrol-based 
treatment needs further investigation. Moreover, we did not 
evaluate other biomarkers related to oxidative damage, or 
simultaneously measure these biomarkers in synovial fluid 
that would provide a more accurate determination of 
changes specific to the knee. Also, because of the relatively 
short follow up duration, we did not assess the radiological 
outcomes at the end of the trial. Meanwhile, the strengths 
of the present study include a randomised, multicentre, 
double blinded placebo controlled study design, which 
consider most of the inter-individual variations in parallel 
arm studies. Additionally, we excluded patients who were 
taking any kind of supplements, especially those containing 
polyphenols, or other herbal supplements for pain relief, 
and were therefore able to exclude potential confounding 
by these factors. 
CONCLUSIONS
This pilot study demonstrates evidence of the role of 
resveratrol, when used in combination with meloxicam, in 
improving pain in patients with mild-to-moderate knee OA 
compared with placebo. It also suggests that intervention 
with a dietary supplement, i.e. the addition of resveratrol, 
may have a significant impact on pain and overall quality 
of life in patients with knee OA. 
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